Skip to Main Content

Paper Details

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
J Clin Oncol
421
2018
Author NameAffiliation
Parminder SinghJ. Graham Brown Cancer Center, University of Louisville, Roswell Park Cancer Institute, Mt Sinai School of Medicine, The University of North Carolina at Chapel Hill, Mayo Clinic, University of Iowa Hospitals and Clinics, University of California Los Angeles School of Medicine Omid Hamid, The Angeles Clinic and Research Institute, MD Anderson Cancer Center, University Hospital Tuebingen, University of Kiel, Indiana University Simon Cancer Center, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la Recherche Medicale U, University of Utah, Rutgers Cancer Institute of New Jersey
  • 1 - 1

Datasets